RECEIVED
CENTRAL FAX CENTER
NOV 0 1 2004

AMENDMENTS TO THE CLAIMS:

Set I: attenuated tumor-targeted bacteria

1. (Canceled)

2. (Original) An attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe.

3. (Canceled)

4. (Canceled)

5. (Previously presented) An attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe and at least one of the primary effector molecules is an anti-angiogenic factor.

6. (Previously presented) The attenuated tumor-targeted bacteria of claim 5, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a

small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

7.-11. (Canceled)

12. (Previously Presented) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

13. (Canceled)

14. (Previously presented) The attenuated tumor-targeted bacteria of claim 2, wherein the attenuated tumor-targeted bacteria is Salmonella.

15. (Canceled)

16. (Previously Presented) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

17.-25. (Canceled)

Set II: Composition

26. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe.

27. (Canceled)

28. (Canceled)

29. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising one or more

nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe and at least one of the primary effector molecules is an anti-angiogenic factor.

30. (Previously presented) The pharmaceutical composition of claim 29, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

31.-35. (Canceled)

36. (Previously Presented) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

37. (Canceled)

38. (Previously Presented) The pharmaceutical composition of claim 26, wherein the attenuated tumor-targeted bacteria is Salmonella.

39. (Canceled)

40. (Previously Presented) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

41.-48. (Canceled)

Set III: Method

49. (Previously presented) A method for delivering one or more primary effector molecules and one or more secondary effector molecules to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe.

50. (Canceled)

51. (Canceled)

52. (Previously presented) A method for delivering one or more primary effector molecules and one or more secondary molecules to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules and one or more secondary effector molecules operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is a facultative aerobe or facultative anaerobe and at least one of the primary effector molecules is an anti-angiogenic factor.

53. (Previously presented) The method of claim 52, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

54.-58. (Canceled)

59. (Previously Presented) The method of claim 49, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

60. (Canceled)

61. (Previously Presented) The method of claim 49, wherein the attenuated tumor-targeted bacteria is Salmonella.

62. (Canceled)

63. (Original) The method of claim 49, wherein at least one of the secondary effector molecules is a bacteriocin release factor.

64.-99. (Canceled)

100.-104. (Canceled)

105. (Previously Presented) The attenuated tumor targeted bacteria of claim 16, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

106.-117. (Canceled)

118. (Previously Presented) The pharmaceutical composition of claim 40, wherein the BRP protein is obtainable from cloacin DF13.

119.-130. (Canceled)

131. (Previously Presented) The method of claim 63, wherein the BRP protein is obtainable from cloacin DF13.

132.-141. (Canceled)

Set IV: Directed to Claim 5

142.-143. (Canceled)

144. (Previously presented) The attenuated tumor-targeted bacteria of claim 5, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

145. (Previously presented) The attenuated tumor-targeted bacteria of claim 5, wherein the anti-angiogenic factor is endostatin.

146. (Previously presented) The attenuated tumor-targeted bacteria of claim 5, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

147. (Previously presented) The attenuated tumor-targeted bacteria of claim 145, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

148. (Previously presented) The attenuated tumor-targeted bacteria of claim 146, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

149. (Previously presented) The attenuated tumor-targeted bacteria of claim 147, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

150. (Previously presented) The attenuated tumor-targeted bacteria of claim 5, wherein the attenuated tumor-targeted bacteria is Salmonella.

151. (Previously presented) The attenuated tumor-targeted bacteria of claim 146, wherein the attenuated tumor-targeted bacteria is Salmonella.

152. (Previously presented) The attenuated tumor-targeted bacteria of claim 147, wherein the attenuated tumor-targeted bacteria is Salmonella.

153. (Previously presented) The attenuated tumor-targeted bacteria of claim 150, wherein the Salmonella is an msbB Salmonella mutant.

154. (Previously presented) The attenuated tumor-targeted bacteria of claim 151, wherein the Salmonella is an msbB Salmonella mutant.

155. (Previously presented) The attenuated tumor-targeted bacteria of claim 152, wherein the Salmonella is an msbB Salmonella mutant.

Set V: Directed to Claim 29

156.-157. (Canceled)

158. (Previously presented) The pharmaceutical composition of claim 29, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

159. (Previously presented) The pharmaceutical composition of claim 29, wherein the anti-angiogenic factor is endostatin.

160. (Previously presented) The pharmaceutical composition of claim 29, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

161. (Previously presented) The pharmaceutical composition of claim 159, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

162. (Previously presented) The pharmaceutical composition of claim 160, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

163. (Previously presented) The pharmaceutical composition of claim 161, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

164. (Previously presented) The pharmaceutical composition of claim 29, wherein the attenuated tumor-targeted bacteria is Salmonella.

165. (Previously presented) The pharmaceutical composition of claim 160, wherein the attenuated tumor-targeted bacteria is Salmonella.

166. (Previously presented) The pharmaceutical composition of claim 161, wherein the attenuated tumor-targeted bacteria is Salmonella.

167. (Previously presented) The pharmaceutical composition of claim 164, wherein the Salmonella is an msbB Salmonella mutant.

168. (Previously presented) The pharmaceutical composition of claim 165, wherein the Salmonella is an msbB Salmonella mutant.

169. (Previously presented) The pharmaceutical composition of claim 166, wherein the Salmonella is an msbB Salmonella mutant.

Set VI: Directed to Claim 52

170.-171. (Canceled)

172. (Previously presented) The method of claim 52, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

173. (Previously presented) The method of claim 52, wherein the anti-angiogenic factor is endostatin.

174. (Previously presented) The method of claim 52, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

175. (Previously presented) The method of claim 173, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

176. (Previously presented) The method of claim 174, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

177. (Previously presented) The method of claim 175, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

178. (Previously presented) The method of claim 52, wherein the attenuated tumor-targeted bacteria is Salmonella.

179. (Previously presented) The method of claim 174, wherein the attenuated tumor targeted bacteria is Salmonella.

180. (Previously presented) The method of claim 175, wherein the attenuated tumor targeted bacteria is Salmonella.

181. (Previously presented) The method of claim 178, wherein the Salmonella is an msbB Salmonella mutant.

182. (New) The method of claim 179, wherein the Salmonella is an msbB Salmonella mutant.

183. (Previously presented) The method of claim 180, wherein the Salmonella is an msbB Salmonella mutant.

184. (Previously presented) The method of claim 52, wherein the solid tumor is a sarcoma or carcinoma.

185. (Previously presented) The method of claim 52, wherein the solid tumor is a tumor of the central nervous system.

breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma, renal cancer, bladder cancer or mesothelioma,

186. (Previously presented) The method of claim 52, wherein the subject is a human.

187. (Previously presented) The method of claim 174, wherein the subject is a human.

188. (Previously presented) The method of claim 175, wherein the subject is a human.

Please add new claims 189-248, as follows:

Set VII

189. (New) An attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella and the primary effector molecule is an anti-angiogenic factor.

190. (New) The attenuated tumor-targeted bacteria of claim 189, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD

containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

191. (New) The attenuated tumor-targeted bacteria of claim 189, wherein the secondary effector molecule is bacteriocin release factor (BRP).

192. (New) The attenuated tumor-targeted bacteria of claim 190, wherein the secondary effector molecule is bacteriocin release factor (BRP).

193. (New) The attenuated tumor-targeted bacteria of claim 191, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

194. (New) The attenuated tumor-targeted bacteria of claim 192, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

195. (New) The attenuated tumor-targeted bacteria of claim 189, wherein the Salmonella is an msbB Salmonella mutant.

196. (New) The attenuated tumor-targeted bacteria of claim 191, wherein the Salmonella is an msbB Salmonella mutant.

197. (New) The attenuated tumor-targeted bacteria of claim 192, wherein the Salmonella is an msbB Salmonella mutant.

198. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said

attenuated tumor-targeted bacteria is Salmonella and the primary effector molecule is an anti-angiogenic factor.

199. (New) The pharmaceutical composition of claim 198, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

200. (New) The pharmaceutical composition of claim 198, wherein the secondary effector molecule is bacteriocin release factor (BRP).

201. (New) The pharmaceutical composition of claim 199, wherein the secondary effector molecule is bacteriocin release factor (BRP).

202. (New) The pharmaceutical composition of claim 200, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

203. (New) The pharmaceutical composition of claim 201, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

204. (New) The pharmaceutical composition of claim 198, wherein the Salmonella is an msbB Salmonella mutant.

205. (New) The pharmaceutical composition of claim 200, wherein the Salmonella is an msbB Salmonella mutant.

206. (New) The pharmaceutical composition of claim 201, wherein the Salmonella is an msbB Salmonella mutant.

207. (New) A method for delivering a primary effector molecule and a secondary molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella and the primary effector molecule is an anti-angiogenic factor.

208. (New) The method of claim 207, wherein the anti-angiogenic factor is endostatin, angiostatin, anti-angiogenic antithrombin III, the 29 kDa N-terminal proteolytic fragment of fibronectin, a 40 kDa C-terminal proteolytic fragment of fibronectin, a uPA receptor antagonist, the 16 kDa proteolytic fragment of prolactin, the 7.8 kDa proteolytic fragment of platelet factor-4, the anti-angiogenic 24 amino acid fragment of platelet factor-4, the anti-angiogenic factor designated 13.40, the anti-angiogenic 22 amino acid peptide fragment of thrombospondin I, the anti-angiogenic 20 amino acid peptide fragment of SPARC, an RGD containing peptide, an NGR containing peptide, a small anti-angiogenic peptide of laminin, a small anti-angiogenic peptide of fibronectin, a small anti-angiogenic peptide of procollagen, a small anti-angiogenic peptide of EGF, apomigren, a peptide antagonist of integrin $\alpha_v\beta_3$, or a peptide antagonist of VEGF receptor.

209. (New) The method of claim 207, wherein the secondary effector molecule is bacteriocin release factor (BRP).

210. (New) The method of claim 208, wherein the secondary effector molecule is bacteriocin release factor (BRP).

211. (New) The method of claim 209, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

212. (New) The method of claim 210, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

213. (New) The method of claim 207, wherein the Salmonella is an msbB Salmonella mutant.

214. (New) The method of claim 209, wherein the Salmonella is an msbB Salmonella mutant.

215. (New) The method of claim 210, wherein the Salmonella is an msbB Salmonella mutant.

Set VIII

216. (New) An attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella and said primary effector molecule is endostatin, platelet factor-4, apomigren, or thrombospondin I.

217. (New) The attenuated tumor-targeted bacteria of claim 216, wherein the secondary effector molecule is bacteriocin release factor (BRP).

218. (New) The attenuated tumor-targeted bacteria of claim 217, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

219. (New) The attenuated tumor-targeted bacteria of claim 216, wherein the Salmonella is an msbB Salmonella mutant.

220. (New) The attenuated tumor-targeted bacteria of claim 217, wherein the Salmonella is an msbB Salmonella mutant.

221. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella and the primary effector molecule is endostatin, platelet factor-4, apomigren, or thrombospondin I.

222. (New) The pharmaceutical composition of claim 221, wherein the secondary effector molecule is bacteriocin release factor (BRP).

223. (New) The pharmaceutical composition of claim 222, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

224. (New) The pharmaceutical composition of claim 221, wherein the Salmonella is an msbB Salmonella mutant.

225. (New) The pharmaceutical composition of claim 222, wherein the Salmonella is an msbB Salmonella mutant.

226. (New) A method for delivering a primary effector molecule and a secondary molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella and the primary effector molecules is endostatin, platelet factor-4, apomigren, or thrombospondin I.

227. (New) The method of claim 226, wherein the secondary effector molecule is bacteriocin release factor (BRP).

228. (New) The pharmaceutical composition of claim 227, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

229. (New) The method of claim 226, wherein the Salmonella is an msbB Salmonella mutant.

230. (New) The method of claim 227, wherein the Salmonella is an msbB Salmonella mutant.

Set IX

231. (New) An attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, platelet factor-4, apomigren, or thrombospondin I, and said secondary effector molecule is bacteriocin release factor (BRP).

232. (New) The attenuated tumor-targeted bacteria of claim 231, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

233. (New) The attenuated tumor-targeted bacteria of claim 231, wherein the Salmonella is an msbB Salmonella mutant.

234. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, platelet factor-4, apomigren, or thrombospondin I, and said secondary effector molecule is bacteriocin release factor (BRP).

235. (New) The pharmaceutical composition of claim 234, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

236. (New) The pharmaceutical composition of claim 234, wherein the Salmonella is an msbB Salmonella mutant.

237. (New) A method for delivering a primary effector molecule and a secondary molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule and a secondary effector molecule operably linked to one or more promoters, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecules is endostatin, platelet factor-4, apomigren, or thrombospondin I, and said secondary effector molecules is bacteriocin release factor (BRP).

238. (New) The pharmaceutical composition of claim 237, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

239. (New) The method of claim 237, wherein the Salmonella is an msbB Salmonella mutant.

Set X

240. (New) An attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule operably linked to a promoter, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, and said secondary effector molecules is bacteriocin release factor (BRP).

241. (New) The attenuated tumor-targeted bacteria of claim 240, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

242. (New) The attenuated tumor-targeted bacteria of claim 240, wherein the Salmonella is an msbB Salmonella mutant.

243. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule operably linked to a promoter, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecule is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).

244. (New) The pharmaceutical composition of claim 243, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

245. (New) The pharmaceutical composition of claim 243, wherein the Salmonella is an msbB Salmonella mutant.

246. (New) A method for delivering a primary effector molecule to a subject to treat a solid tumor cancer, comprising administering to said subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated tumor-targeted bacteria comprising a nucleic acid molecule encoding a primary effector molecule operably linked to a promoter, wherein said attenuated tumor-targeted bacteria is Salmonella, said primary effector molecules is endostatin, and said secondary effector molecule is bacteriocin release factor (BRP).

247. (New) The pharmaceutical composition of claim 246, wherein the BRP protein is obtainable from the cloacin DF13 plasmid.

248. (New) The method of claim 246, wherein the Salmonella is an msbB Salmonella mutant.